摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-氯-1-[4-(2-甲基-2-丙基)苯基]-1-丙酮 | 28547-33-3

中文名称
3-氯-1-[4-(2-甲基-2-丙基)苯基]-1-丙酮
中文别名
——
英文名称
1-(4-(tert-butyl)phenyl)-3-chloropropan-1-one
英文别名
1-(4-T-Butylphenyl)-3-chloropropan-1-one;1-(4-tert-butylphenyl)-3-chloropropan-1-one
3-氯-1-[4-(2-甲基-2-丙基)苯基]-1-丙酮化学式
CAS
28547-33-3
化学式
C13H17ClO
mdl
——
分子量
224.73
InChiKey
RWKVKFPYVTZRHS-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.8
  • 重原子数:
    15
  • 可旋转键数:
    4
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.46
  • 拓扑面积:
    17.1
  • 氢给体数:
    0
  • 氢受体数:
    1

安全信息

  • 海关编码:
    2914700090

SDS

SDS:91afe79bbad8da09b0886f395896d5fd
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 1-(4-t-Butylphenyl)-3-chloropropan-1-one
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 1-(4-t-Butylphenyl)-3-chloropropan-1-one
CAS number: 28547-33-3

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C13H17ClO
Molecular weight: 224.7

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen chloride.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    参考文献:
    名称:
    大规模不对称合成香草醛受体(TRPV1)拮抗剂ABT-102的开发
    摘要:
    开发了高效的TRPV1拮抗剂ABT-102不对称合成物,并成功地在多千克规模上得到了证明。该方法结合了(R)-叔丁基氨基茚满的新的不对称合成,其基于手性辅助诱导的亚氨基茚满的前体的非对映选择性还原。
    DOI:
    10.1021/op060228s
  • 作为产物:
    参考文献:
    名称:
    鉴定(R)-1-(5-叔丁基-2,3-二氢-1H-茚满-1-基)-3-(1H-吲唑-4-基)脲(ABT-102)为有效的TRPV1拮抗剂用于疼痛处理。
    摘要:
    Vanilloid受体TRPV1是一个阳离子通道,可被多种有害刺激物(包括辣椒素,酸和热)激活。几家制药公司正在研究选择性拮抗剂对TRPV1激活的阻断作用,以寻找用于疼痛治疗的新型药物。在这里我们报告说,在先前描述的N-吲唑-N'-苄基脲系列中,茚满刚性部分取代了取代的苄基,导致许多TRPV1拮抗剂具有显着提高的体外效力和增强的类药物特性。对合成类似物的药理,药代动力学和毒理学性质进行了广泛的评估,结果鉴定出(R)-7(ABT-102)。(R)-7的镇痛活性和类药物特性均支持其在临床疼痛试验中的发展。
    DOI:
    10.1021/jm701007g
点击查看最新优质反应信息

文献信息

  • Prodrugs of compounds that inhibit TRPV1 receptor
    申请人:Gomtsyan R. Arthur
    公开号:US20070099954A1
    公开(公告)日:2007-05-03
    Compounds of formula (I) wherein A, R 1 , R 2 , and R 3 are defined in the specification, and which are useful as therapeutic compounds particularly for treating disorders or conditions associated with inflammation, pain, bladder overactivity, urinary incontinence, and other disorders caused by or exacerbated by TRPV1.
    式(I)的化合物 其中A,R1,R2和R3在规范中定义,并且这些化合物可用作治疗化合物,特别用于治疗与炎症、疼痛、膀胱过度活动、尿失禁以及由TRPV1引起或加重的其他疾病或症状相关的紊乱。
  • PYRAZOLO[3,4-b]PYRIDINE AND PYRROLO[2,3-b]PYRIDINE INHIBITORS OF BRUTON'S TYROSINE KINASE
    申请人:Pharmacyclics LLC
    公开号:US20180194762A1
    公开(公告)日:2018-07-12
    Disclosed are pyrazolo[3,4-b]pyridine and pyrrolo[2,3-b]pyridine inhibitors of Bruton's tyrosine kinase (Btk). Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are described, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    公开了吡唑并[3,4-b]吡啶和吡咯并[2,3-b]吡啶作为布鲁顿酪氨酸激酶(Btk)的抑制剂。还公开了包含这些化合物的药物组合物。描述了使用Btk抑制剂的方法,单独使用或与其他治疗剂联合使用,用于治疗自身免疫性疾病或状况、异体免疫性疾病或状况、癌症(包括淋巴瘤)和炎症性疾病或状况。
  • Mn-Enabled Radical-Based Alkyl–Alkyl Cross-Coupling Reaction from 4-Alkyl-1,4-dihydropyridines
    作者:Jie Wang、Yu-Bo Pang、Na Tao、Run-Sheng Zeng、Yingsheng Zhao
    DOI:10.1021/acs.joc.9b02323
    日期:2019.12.6
    efficient alkylation of β-chloro ketones and their derivatives was achieved by means of domino dehydrochlorination/Mn-enabled radical-based alkyl-alkyl cross-coupling reaction. In situ-generated α,β-unsaturated ketones and their analogues were identified as the reaction intermediates. Known bioactive compounds, such as melperone and azaperone, could be easily prepared from β-chloropropiophenone in two
    β-氯酮及其衍生物的高效烷基化是通过多米诺脱氢/基于锰的自由基基烷基-烷基交叉偶联反应实现的。原位生成的α,β-不饱和酮及其类似物被确定为反应中间体。已知的生物活性化合物,例如美蓬酮和氮杂哌酮,可以很容易地由β-氯丙苯酮分两步制备。
  • [EN] SUBSTITUTED BICYCLIC CARBOXAMIDE AND UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS<br/>[FR] DÉRIVÉS BICYCLIQUES SUBSTITUÉS DE CARBOXAMIDE ET D'URÉE EN TANT QUE LIGANDS DU RÉCEPTEUR VANILLOÏDE
    申请人:GRUENENTHAL GMBH
    公开号:WO2012062463A1
    公开(公告)日:2012-05-18
    The invention relates to substituted bicyclic carboxamide and urea derivatives, to processes for the preparation thereof, to pharmaceutical compositions containing these compounds and also to the use of these compounds for preparing pharmaceutical compositions.
    本发明涉及取代的双环羧酰胺和尿素衍生物,其制备方法,包含这些化合物的药物组合物,以及使用这些化合物制备药物组合物的用途。
  • Substituted Bicyclic Carboxamide and Urea Compounds as Vanilloid Receptor Ligands
    申请人:FRANK Robert
    公开号:US20120115893A1
    公开(公告)日:2012-05-10
    Substituted bicyclic carboxamide and urea compounds corresponding to formula (I) processes for the preparation thereof, pharmaceutical compositions containing these compounds, and a method of using these compounds for the treatment and/or inhibition of pain and other conditions mediated at least in part via the vanilloid receptor 1.
    取代的二环状羧酰胺和尿素化合物,对应于公式(I),其制备方法,包含这些化合物的药物组合物,以及使用这些化合物治疗和/或抑制至少部分通过香草酸受体1介导的疼痛和其他条件的方法。
查看更多